Orphazyme, a Danish biotech company with a late stage orphan drug pipeline, today published an offering circular and the indicative price range in connection with its intended initial public offering (“IPO” or the “Offering”) and subsequent admission to trading and official listing of its shares on Nasdaq Copenhagen.
The indicative offer price range is DKK 64 to DKK 80 per share of nominal value DKK 1 each, and commitments to subscribe for a number of shares in the Offering, subject to certain conditions, have already been expressed by SEB, Vækstfonden, BankInvest on behalf of certain clients, Handelsbanken and Spar Nord – corresponding to DKK 230 million.